Skip to content

Study · Measured the body's own peptide · 1988

4 results

Neurophysins as tumor markers for small cell carcinoma of the lung. A cancer and Leukemia Group B evaluation.

North WG, Ware J, Maurer LH, Chahinian AP, Perry M

Cancer1 Oct 1988Cited by 16 (Europe PMC)

PMID2843278 (opens in a new tab)DOI10.1002/1097-0142(19881001)62:7<1343::aid-cncr2820620717>3.0.co;2-h (opens in a new tab)PepBankPUB-02843278
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    Before treatment, 14% of small cell lung carcinoma tumours secreted oxytocin-associated neurophysin and 11% produced both vasopressin- and oxytocin-associated neurophysins.

    In plain wordsIn people with small cell lung cancer, 14% of tumours released a protein tied to the body's own oxytocin before treatment.

    Peptide
    Oxytocin
    Outcome
    Not applicableOxytocin-associated neurophysin secretion by small cell lung tumours
    Study

    n: not reported in source

    Outcome group
    Endogenous peptide levels · Cancer

    Measurements

    Tumours secreting OT-HNP
    14%
    pretreatment plasma
    Tumours producing both HNPs
    11%
    pretreatment plasma

    Source sentences

    Summary
    14% secreting oxytocin-associated HNP (OT-HNP), and 11% producing both HNPs
    1 context sentence
    Summary · context
    Plasma human neurophysins (HNPs) were evaluated as tumor markers for patients with small cell carcinoma of the lung (SCCL) who were entered on limited disease and extensive disease treatment trials conducted by Cancer and Acute Leukemia Group B (CALGB).

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

Studies that did not test the peptide alone3

In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Oxytocin.

  1. 02HumanNot a test of Oxytocin aloneObservational studyOther

    Human neurophysin-secreting tumours were more frequent in patients with extensive disease and two or more metastatic lesions than in patients with limited disease.

    In plain wordsTumours that released neurophysin proteins were more common in people with advanced small cell lung cancer than in people with limited disease.

    Peptide
    Oxytocin
    Outcome
    IncreaseNeurophysin-secreting tumours by disease extent
    Study

    n: not reported in source

    Outcome group
    Endogenous peptide levels · Cancer

    Source sentences

    Summary
    There was a significantly higher incidence of HNP-secreting tumors for patients with extensive disease and two or more metastatic lesions than for patients with limited disease.
    1 context sentence
    Summary · context
    Plasma human neurophysins (HNPs) were evaluated as tumor markers for patients with small cell carcinoma of the lung (SCCL) who were entered on limited disease and extensive disease treatment trials conducted by Cancer and Acute Leukemia Group B (CALGB).

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  2. 03HumanNot a test of Oxytocin aloneObservational studyOther

    Response to treatment and survival did not clearly differ between patients with neurophysin-secreting tumours and those with nonsecreting tumours.

    In plain wordsResponse to treatment and survival were not clearly different between people whose tumours released neurophysins and people whose tumours did not.

    Peptide
    Oxytocin
    Outcome
    No significant changeTreatment response and survival by neurophysin secretion
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    There were no clear differences in response to treatment or in survival between patients with HNP-secreting tumors and those with nonsecreting tumors.
    1 context sentence
    Summary · context
    Plasma human neurophysins (HNPs) were evaluated as tumor markers for patients with small cell carcinoma of the lung (SCCL) who were entered on limited disease and extensive disease treatment trials conducted by Cancer and Acute Leukemia Group B (CALGB).

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  3. 04HumanNot a test of Oxytocin aloneObservational studyOther

    Change in plasma neurophysin gave 91% agreement with independently derived clinical impressions of treatment response.

    In plain wordsChanges in blood neurophysin matched doctors' independent view of treatment response in 91% of cases.

    Peptide
    Oxytocin
    Outcome
    Not applicableAgreement of plasma neurophysin change with clinical impression
    Study

    n: not reported in source

    Outcome group
    Endogenous peptide levels · Cancer

    Measurements

    Agreement
    91%
    plasma HNP change vs clinical impression

    Source sentences

    Summary
    Response to treatment evaluated by the change in plasma HNP, gave a 91% agreement with independently derived clinical impressions.
    1 context sentence
    Summary · context
    Plasma human neurophysins (HNPs) were evaluated as tumor markers for patients with small cell carcinoma of the lung (SCCL) who were entered on limited disease and extensive disease treatment trials conducted by Cancer and Acute Leukemia Group B (CALGB).

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 20:03 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:54 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.